Chemomab Therapeutics Ltd.

CMMB

US16385C2035

Biotechnology & Medical Research

Delayed Nasdaq Other stock markets 12:13:48 2025-12-05 pm EST			5-day change	1st Jan Change
2.500 ^USD	+1.21%		-4.58%	-65.47%

Dec. 02	Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology	CI
Dec. 02	Chemomab Therapeutics announces nebokitug phase 2 spring trial results	RE

Chemomab Therapeutics to Raise $10 Million From Private Placement; Shares Fall

Published on 07/25/2024 at 02:04 pm EDT - Modified on 07/25/2024 at 02:18 pm EDT

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Chemomab Therapeutics Ltd.

Dec. 02	Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology	CI
Dec. 02	Chemomab Therapeutics announces nebokitug phase 2 spring trial results	RE
Nov. 20	Chemomab Therapeutics Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
Nov. 20	Chemomab Therapeutics announces third quarter 2025 financial results and provides corporate update	RE
Nov. 06	Chemomab announces multiple presentations at AASLD The Liver Meeting 2025 featuring clinical data from the Nebokitug phase 2 trial in Primary Sclerosing Cholangitis	RE
Aug. 14	Chemomab Therapeutics Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
Jun. 30	Chemomab Therapeutics, Ltd. Announces Oral Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis At Bsg Live'25	CI
Jun. 11	Chemomab Therapeutics Ltd. Reports Positive Feedback from Two Recent FDA Meetings Supporting Phase 3 Advancement of Nebokitug in Primary Sclerosing Cholangitis	CI
Jun. 03	Chemomab Therapeutics Says Nebokitug Awarded New Patent Protections in China, Russia	MT
May. 16	Oppenheimer Adjusts Chemomab Therapeutics Price Target to $10 From $11, Maintains Outperform Rating	MT
May. 15	Chemomab Therapeutics Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
May. 05	Chemomab Therapeutics, Ltd. Announces Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis in Distinguished Plenary Session at DDW 2025	CI
Apr. 28	Chemomab Therapeutics Reports Positive Data on Liver Disease Treatment	MT
Apr. 15	Chemomab Therapeutics Names David Weiner as Interim Chief Medical Officer	MT
Apr. 15	Chemomab Therapeutics, Ltd. Announces Management Changes	CI
Mar. 27	Chemomab Reports Positive Results In Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad And Substantial Improvements In Key Liver Biomarkers	RE
Mar. 27	Chemomab Reports Positive Results in Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad and Substantial Improvements in Key Liver Biomarkers	CI
Mar. 06	Chemomab Therapeutics, Ltd. Announces New Scientific Presentation That Further Confirms the Potential of Nebokitug (CM-101) as a Novel Treatment for Systemic Sclerosis	CI
Mar. 03	Chemomab Therapeutics Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024	CI
Feb. 19	Chemomab Therapeutics Ltd. Successful End-of-Phase 2 Meeting and Aligns with FDA on Clear and Efficient Path to Potential Regulatory Approval for Nebokitug (CM-101) in Primary Sclerosing Cholangitis	CI
Nov. 19	Chemomab Therapeutics Ltd. Announces Data from its Phase 2 SPRING Trial in Patients with Primary Sclerosing Cholangitis	CI
Nov. 15	Oppenheimer Adjusts Chemomab Therapeutics Price Target to $11 From $13, Maintains Outperform Rating	MT
24-08-21	Chemomab Therapeutics Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI
24-07-29	Chemomab Therapeutics Ltd. announced that it has received $9.999607 million in funding	CI
24-07-25	Chemomab Therapeutics to Raise $10 Million From Private Placement; Shares Fall	MT

Chart Chemomab Therapeutics Ltd.

Duration

Period

CMMB: Dynamic Chart

Chemomab Therapeutics Ltd, formerly known as Anchiano Therapeutics Ltd, is a Israel-based biopharmaceutical company. The Company specializes in the development of patient oriented targeted therapy for the treatment of a wide range of cancers. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.

Employees

Sector

Biotechnology & Medical Research

Calendar

Dec. 11 - Oppenheimer Movers in Rare Disease Summit

More about the company